Table 4

HRs and 95% CIs for the association between frequency and duration of PPIs use and risk of gastric cancer (propensity score adjustment with trimming)

PPIs frequencyDose–response relationship (n=57 057, GC=139)
HR95% CIp Value
Non-user (<weekly use)Ref
Weekly to <daily2.431.37 to 4.310.002
Daily4.551.12 to 18.520.034
PPIs frequencyPPIs use ≥1 year (n=50 932, GC=112)PPIs use ≥2 years (n=49 462, GC=88)PPIs use ≥3 years (n=48 511, GC=69)
HR95% CIp ValueHR95% CIp ValueHR95% CIp Value
Non-user (<weekly use)RefRefRef
Weekly to <daily1.810.90–3.640.0980.980.31–3.170.9790.580.08–4.230.590
Daily5.041.23–20.61 0.024 6.651.62–27.26 0.009 8.342.02–34.41 0.004
  • Significant p Values were highlighted in bold.

  • GC, gastric cancer; PPIs, proton pump inhibitors.